Nguyen B C, Stanford W, Thompson B H, Rossi N P, Kernstine K H, Kern J A, Robinson R A, Amorosa J K, Mammone J F, Outwater E K
University of Iowa College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
J Magn Reson Imaging. 1999 Sep;10(3):468-73. doi: 10.1002/(sici)1522-2586(199909)10:3<468::aid-jmri31>3.0.co;2-i.
The purpose of this study was to evaluate the clinical efficacy of ultrasmall superparamagnetic iron oxide particles as a magnetic resonance (MR) contrast agent in differentiating metastatic from benign lymph nodes. Eighteen patients with primary lung malignancy and suspected regional lymph node metastases underwent MR imaging before and after Combidex(R) infusion in a multi-institutional study. All MR sequences were interpreted by one or more board-certified radiologists experienced in imaging thoracic malignancy. Each patient was evaluated for the number and location of lymph nodes, homogeneity of nodal signal, and possible change of MR signal post contrast. All patients underwent resection or sampling of the MR-identified lymph node(s) 1-35 day(s) post contrast MR imaging. In all, 27 lymph nodes or nodal groups were available for histopathologic correlation. Combidex had a sensitivity of 92% and a specificity of 80% in identifying pathologically confirmed metastatic mediastinal lymph nodes. Based on our preliminary data, Combidex MR imaging may provide additional functional information useful in the staging of mediastinal lymph nodes.
本研究的目的是评估超小超顺磁性氧化铁颗粒作为磁共振（MR）造影剂在鉴别转移性淋巴结与良性淋巴结方面的临床疗效。在一项多机构研究中，18例原发性肺癌且怀疑有区域淋巴结转移的患者在输注Combidex®前后接受了MR成像检查。所有MR序列均由一名或多名在胸部恶性肿瘤成像方面经验丰富的经委员会认证的放射科医生解读。对每位患者的淋巴结数量和位置、淋巴结信号均匀性以及造影剂注射后MR信号的可能变化进行评估。所有患者在造影剂注射后1至35天接受了MR识别的淋巴结的切除或取样。总共有27个淋巴结或淋巴结组可用于组织病理学对照。Combidex在识别经病理证实的转移性纵隔淋巴结方面的敏感性为92%，特异性为80%。基于我们的初步数据，Combidex MR成像可能提供有助于纵隔淋巴结分期的额外功能信息。
